Global Vascular Malformations Drugs Market, By Type (Capillary Vascular Malformations, Spider Angiomas, Venous Malformations, Arteriovenous Malformations, Lymphatic Malformations, Pyogenic Granulomas, Angiofibromas, Glomangiomas, Hemangiomas, Others), Drugs (Sirolimus, Sodium Tetradecyl Sulfate (1%), Ethanol (95%), Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Vascular Malformations Drugs Market Analysis and Size
The global vascular malformations drugs market is expected to witness significant growth during the forecast period. Vascular malformations are congenital vasculogenesis disorders affecting around 0.5% of the population. Although benign, lesions cause major morbidity, primarily because they enlarge over time. The healthcare professionals who focus on patients having vascular malformations recognize that these lesions are not static. The increasing prevalence of chronic diseases, such as cancer and vascular diseases, drives the vascular malformation drug market.
Data Bridge Market Research analyses a growth rate in the global vascular malformations drugs market in 2023-2030. The expected CAGR of the global vascular malformations drugs market tends to be around 6.50% in the mentioned forecast period. The market was valued at USD 2.71 billion in 2022 and would grow to USD 4.50 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Vascular Malformations Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Capillary Vascular Malformations, Spider Angiomas, Venous Malformations, Arteriovenous Malformations, Lymphatic Malformations, Pyogenic Granulomas, Angiofibromas, Glomangiomas, Hemangiomas, Others), Drugs (Sirolimus, Sodium Tetradecyl Sulfate (1%), Ethanol (95%), Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Galderma (Switzerland), Abbvie, Inc. (U.S.), Bausch Health Companies Inc. (U.S.)., Bristol Myers Squibb Company (U.S.) Fresenius Kabi AG (Germany), Merck KGaA (Germany), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Accord Healthcare (U.K.), Zydus Group (India), Dr Reddy's Laboratories Ltd (India), Amneal Pharmaceuticals LLC. (U.S.), Apotex Inc (Canada)
|
|
Market Opportunities
|
|
Market Definition
Vascular malformations are the kind of birthmark or growth, such as blemish or mass, that may cause pain, swelling, or bleeding. Vascular malformations often result from abnormal development in blood vessels, lymph vessels, veins, and arteries. Vascular malformations are usually present at birth; the abnormalities grow proportionally with the child. Vascular malformations are differentiated from vascular tumors based on endothelial proliferation.
Global Vascular Malformations Drugs Market Dynamics
Drivers
- Growing cases of vascular malformations
Venous malformation (V.M.) is the most common type of congenital vascular malformation (CVM), with an occurrence of 1 to 2 in 10,000 and an incidence of 1%. Some of its types are found in less than 1 percent of the population. Thus, this boosts market growth.
- Huge demand for diagnostic tests
The increasing demand for several diagnostic tests such as g ultrasound, MRI, and/or angiography are driving the market's growth. Angiography involves the injection of a dye, which will outline the blood vessels on an X-ray; thus, these diagnostic tests are pushing the market growth.
Opportunities
- Increasing demand for retail pharmacies
The rise in the number of medications for vascular malformations delivered through these retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
- Varied treatment methods for vascular malformations
Diverse treatment methods are working well for the patients, such as embolization, sclerotherapy, laser, and resection, which will create more opportunities for market growth. Sclerotherapy successfully treats varicose and spider veins. It's often considered the ultimate treatment of choice for small varicose veins.
Restraints/Challenges
- Side effects of vascular malformations drugs
There are several side effects that are associated with vascular malformation drugs. Vascular malformations drugs can lead to headaches, dizziness, vision problems, and seizures which somewhat hamper the market growth.
- High cost of treatment
The huge expenditure on treatment methods hampers the market growth. Several treatment options, such as varied surgeries and therapies, are not so cost-effective and thus hinder the market's growth.
This global vascular malformations drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vascular malformations drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Vascular Malformations Drugs Market Scope
The global vascular malformations drugs market is segmented on the basis of type, drugs, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Capillary Vascular Malformations
- Spider Angiomas, Venous Malformations
- Arteriovenous Malformations
- Lymphatic Malformations
- Pyogenic Granulomas
- Angiofibromas
- Glomangiomas
- Hemangiomas
- Others
Drugs
- Sirolimus
- Sodium Tetradecyl Sulfate (1%)
- Ethanol (95%)
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Vascular Malformations Drugs Market Regional Analysis/Insights
The global vascular malformations drugs market is analysed and market size insights and trends are provided by type, drugs, distribution channel and end-user as referenced above.
The major countries covered in the global vascular malformations drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increased healthcare and R&D expenditure and the presence of skilled professionals.
Asia-Pacific dominates the market due to increased general skin problems, increased awareness for vascular malformations through advertisement and media, and rapidly improving healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Vascular Malformations Drugs Market Share Analysis
The global vascular malformations drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vascular malformations drugs market.
Key players operating in the global vascular malformations drugs market include:
- Galderma (Switzerland)
- Abbvie, Inc. (U.S.)
- Bausch Health Companies Inc. (U.S.).
- Bristol Myers Squibb Company (U.S.)
- Fresenius Kabi AG (Germany)
- Merck KGaA (Germany)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.),
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Accord Healthcare (U.K.)
- Zydus Group (India)
- Dr Reddy's Laboratories Ltd (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Apotex Inc (Canada)
SKU-